Implementing national cancer control plans
Dr Eduardo Cazap and Dr Lisa Stevens
24 Jun 2019
The potential of PARP inhibitors in new cancer groups and in combination with ot...
Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston,...
18 Jun 2019
Anti-tumour activity of TAK-788 in NSCLC patients with EGFR exon 20 insertions
Dr Joel Neal - Stanford University, Stanford, USA
18 Jun 2019
A phase II study of bemcentinib with pembrolizumab in patients with advanced NSC...
Dr Enriqueta Felip - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spai...
11 Jun 2019
Pembrolizumab increases long-term survival in patients with advanced NSCLC
Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA
11 Jun 2019
Expanding clinical trial eligibility criteria: Risks and solutions
Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA
11 Jun 2019
Carfilzomib and irinotecan in relapsed small cell lung cancer
Dr Susanne Arnold - UK Markey Cancer Center, Lexington, USA
6 Jun 2019
Clinical activity and tolerability of the RET inhibitor BLUE-667 in patients wit...
Dr Justin F. Gainor - Massachusetts General Hospital, Boston, USA
6 Jun 2019
Understanding eligibility criteria for clinical trials to increase study size
Dr R. Donald Harvey - Winship Cancer Institute of Emory University, Druid Hills,...
3 Jun 2019
Expanded clinical trial inclusion criteria would double the percentage of patien...
Dr R. Donald Harvey - Winship Cancer Institute of Emory University, Druid Hills,...
3 Jun 2019
Clinical and translational results from the NEOSTAR study: Treating early-stage ...
Dr Tina Cascone - The University of Texas MD Anderson Cancer Center, Houston, US...
1 Jun 2019
KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as tr...
Dr Edward B. Garon - UCLA, Los Angeles, USA
1 Jun 2019
